Why was the United States asked to suspend the introduction of J&J Covid?

Vaccine against hard

The Johnson & JOHNSON Covid vaccine could be discontinued in the United States, where the Food and Drink Administration (FDA) took a break from “extreme caution.” Suspension of the introduction of the U.S. coronavirus vaccine has been linked to blood clots.

Johnson & Johnson is the first to produce an effective single-dose vaccination against coronavirus. But U.S. authorities have recommended stopping the vaccine when looking at reports of rare blood clots in people who have recently had a shot.

Johnson & Johnson’s Covid vaccine was approved in the United States in late February. However, the vaccine developed by Janssen has not yet been approved for use in the UK.

The British government has pre-ordered 30 million doses of the vaccine. The U.S. Medicines Agency has recommended a “break” in the distribution of the Johnson & Johnson vaccine so they can investigate blood clot reports.

The Food and Beverage Administration (FDA) and the Centers for Disease Control and Prevention (CDC) have recommended suspending the introduction. Rare and severe blood clots have been reported in patients who have recently received the vaccine.


It is still unclear whether blood clots are caused directly by the vaccine. However, because the treatments for these blood clots were different from those for regular blood clots, the FDA and CDC recommended a short break. Nearly seven million doses of Johnson & Johnson vaccine have been given. Six of these were reported in cases of thrombosis in the United States.

The official FDA Twitter account tweeted: “The FDA and @CDCgov today issued a statement on Johnson & Johnson’s #COVID19 vaccine. We recommend that you take a break from using this vaccine as a precaution.

PR. 4/12 were given more, 8 m + doses of J&J vaccine in the United States. The CDC and FDA are reviewing data from six reported cases in the United States where people have a rare and severe blood clot after receiving the vaccine. effects appear to be very rare.

The treatment for this type of blood clot differs from that normally given. The CDC will convene a meeting of the Advisory Committee on Vaccination Practices (ACIP) on Wednesday to examine these cases in more detail and assess their potential significance. The FDA is reviewing this analysis and is also investigating these cases.

“Until this process is complete, we recommend taking this break. “This is important to ensure that the healthcare industry is aware of the potential for these side effects and can design based on the unique treatment required for this type of blood clot.” It remains unclear whether the reported blood clots were related to the same animal species as those associated with AstraZeneca earlier this month.

The European Union healthcare regulator, EMA, has confirmed that the AstraZeneca coronavirus vaccine has been linked to blood clots in cerebral sinus venous thrombosis, but the benefits outweigh the disadvantages. The British Medicines and Healthcare Products Regulatory Authority (MHRA) found that 79 people had developed these rare blood clots after receiving AstraZeneca – 19 of them later died. An alternative to AstraZeneca is now offered to people under 30 in the UK.

About The Author